Macada Holding, Inc. Awards D'Arcy Laboratories With Rights to Manufacture Skin Products
10 August 2010 - 12:48AM
Marketwired
Macada Holding
, Inc. (PINKSHEETS: MCDA) has
decided to award D'Arcy Laboratories a contract to manufacture
treatment lotions, soap and shampoo skin products for the Bio-Skin
line.
The first three treatment products, the shampoo, soap, and
crème, build up and improve the resistance of the skin. These
compounds are suitable in particular for preventive treatment in
cases of predisposition to chronic skin diseases, for the
prevention and treatment of allergic skin reactions, for the
treatment of acute skin injuries, for example burns and wounds, as
well as in anti-aging of the skin, skin cell rejuvenation and in
the treatment of degenerate cells, such as in skin cancers, benign
and/or malignant tumors.
"These products address very large markets," said Ron Ritter,
President of Macada. "With their superior performance, we look
forward to excellent demand."
Inventor Karsten Klingelhöller started his original Regividerm
products in 1984 and tried to license Regividerm to leading
companies without success and finally lost everything. In 2008, he
developed a new and improved product for Lyfetec's Bio-skin line,
adding four new ingredients to rejuvenate infected and damaged
cells with a cell rejuvenator, silver additive and other
FDA-approved ingredients.
Visit our websites at www.lyfetec.com, www.bio-skin.us or
www.thenhscenter.com or www.lyfepet.com and
www.pembrokegunrange.com to find information about ways you can
confirm the benefits of each of the products lines that Lyfetec
offers. Consumers will also find supporting research and documents
that will help them understand how Lyfetec's supplements work to
improve their health, immune system, and overall energy level.
This news release includes forward-looking statements, including
with respect to the future level of business for the parties. These
statements are necessarily subject to risk and uncertainty. Actual
results could differ materially from those projected in these
forward-looking statements as a result of certain risk factors that
could cause results to differ materially from estimated results.
Management cautions that all statements as to future results of
operations are necessarily subject to risks, uncertainties and
events that may be beyond the control of Macada Holding, Inc. and
no assurance can be given that such results will be achieved.
Potential risks and uncertainties include, but are not limited to,
the ability to procure, properly price, retain and successfully
complete projects, the availability of technical personnel, changes
in technology and competition.
Contact: Ron Ritter 954-960-5079
KMA (CE) (USOTC:MCDA)
Historical Stock Chart
From Oct 2024 to Nov 2024
KMA (CE) (USOTC:MCDA)
Historical Stock Chart
From Nov 2023 to Nov 2024